Coherus Biosciences Inc Logo Image

Coherus Biosciences Inc

Most Recent Annual Report

2016 Annual Report, Interactive Annual Report and Form 10K

Coherus Biosciences Inc

Coherus Biosciences Inc does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

  • Coherus Biosciences Inc
  • Coherus Biosciences Inc

About Coherus Biosciences Inc

51-200 Employees
Based in Redwood City, California

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia.

Ticker:
CHRS
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol